Download PDF
Semin Respir Crit Care Med 2012; 33(01): 111-124
DOI: 10.1055/s-0032-1301739
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Infectious Complications after Orthotopic Liver Transplantation

Gopi Patel
1   Department of Medicine, Division of Infectious Diseases, Mount Sinai School of Medicine, New York, New York.
,
Shirish Huprikar
1   Department of Medicine, Division of Infectious Diseases, Mount Sinai School of Medicine, New York, New York.
› Author Affiliations
Further Information

Publication History

Publication Date:
23 March 2012 (online)

    Permissions and Reprints

Abstract

Advances in surgical technique, critical care, immunosuppression, donor and recipient screening, and prophylactic strategies have contributed to the evolving microbiology and epidemiology of infectious complications after liver transplantation. Although decreased overall, infections continue to be a major contributor to graft loss and patient morbidity. Bacterial and candidal infections are less frequent, but antimicrobial resistance has become more common and can potentially limit successful treatment of health care–acquired and surgical site infections. As the transplant population grows, intensivists and pulmonologists are more likely to evaluate liver transplant recipients with infections. Presentations of opportunistic respiratory infections may be atypical in the setting of immunosuppression. Although novel noninvasive diagnostic tools are available for some pathogens, bronchoscopic evaluation may be increasingly helpful in differentiating between certain respiratory pathogens when empirical therapy is plagued by drug interactions and drug toxicities. Knowledge about common postoperative infections and opportunistic respiratory pathogens such as cytomegalovirus and fungi is essential to improving the global care of the liver transplant recipient.

Keywords

liver transplant - bacterial infection - fungal infection - cytomegalovirus
 

  • References

  • 1 Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338 (24) 1741-1751
    CrossrefPubMedGoogle Scholar
  • 2 Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25) 2601-2614
    CrossrefPubMedGoogle Scholar
  • 3 Kusne S, Dummer JS, Singh N , et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore) 1988; 67 (2) 132-143
    PubMedGoogle Scholar
  • 4 Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010; 24 (2) 273-283
    CrossrefPubMedGoogle Scholar
  • 5 Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003; 3 (3) 156-161
    CrossrefPubMedGoogle Scholar
  • 6 Huprikar S. Update in infectious diseases in liver transplant recipients. Clin Liver Dis 2007; 11 (2) 337-354
    CrossrefPubMedGoogle Scholar
  • 7 Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2004; 4 (Suppl 10) 10-20
    CrossrefPubMedGoogle Scholar
  • 8 Kotton CN, Ryan ET, Fishman JA. Prevention of infection in adult travelers after solid organ transplantation. Am J Transplant 2005; 5 (1) 8-14
    CrossrefPubMedGoogle Scholar
  • 9 Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008; 8 (1) 9-14
    PubMedGoogle Scholar
  • 10 Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004; 4 (Suppl 10) 160-163
    PubMedGoogle Scholar
  • 11 Morgan JS, Schaffner W, Stone WJ. Opportunistic strongyloidiasis in renal transplant recipients. Transplantation 1986; 42 (5) 518-524
    CrossrefPubMedGoogle Scholar
  • 12 DeVault Jr GA, King JW, Rohr MS, Landreneau MD, Brown III ST, McDonald JC. Opportunistic infections with Strongyloides stercoralis in renal transplantation. Rev Infect Dis 1990; 12 (4) 653-671
    CrossrefPubMedGoogle Scholar
  • 13 Schaeffer MW, Buell JF, Gupta M, Conway GD, Akhter SA, Wagoner LE. Strongyloides hyperinfection syndrome after heart transplantation: case report and review of the literature. J Heart Lung Transplant 2004; 23 (7) 905-911
    CrossrefPubMedGoogle Scholar
  • 14 Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49 (9) 1411-1423
    CrossrefPubMedGoogle Scholar
  • 15 Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis 2003; 5 (1) 3-8
    CrossrefPubMedGoogle Scholar
  • 16 Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis 2008; 21 (4) 415-420
    CrossrefPubMedGoogle Scholar
  • 17 Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 2002; 4 (3) 148-151
    CrossrefPubMedGoogle Scholar
  • 18 Freifeld AG, Iwen PC, Lesiak BL, Gilroy RK, Stevens RB, Kalil AC. Histoplasmosis in solid organ transplant recipients at a large midwestern university transplant center. Transpl Infect Dis 2005; 7 (3-4) 109-115
    CrossrefPubMedGoogle Scholar
  • 19 Clancy CJ, Jaber RA, Leather HL , et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45 (6) 1759-1765
    CrossrefPubMedGoogle Scholar
  • 20 Fischer SA, Graham MB, Kuehnert MJ , et al; LCMV in Transplant Recipients Investigation Team. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006; 354 (21) 2235-2249
    CrossrefPubMedGoogle Scholar
  • 21 Iwamoto M, Jernigan DB, Guasch A , et al; West Nile Virus in Transplant Recipients Investigation Team. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348 (22) 2196-2203
    CrossrefPubMedGoogle Scholar
  • 22 Srinivasan A, Burton EC, Kuehnert MJ , et al; Rabies in Transplant Recipients Investigation Team. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005; 352 (11) 1103-1111
    CrossrefPubMedGoogle Scholar
  • 23 Palacios G, Druce J, Du L , et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008; 358 (10) 991-998
    CrossrefPubMedGoogle Scholar
  • 24 Centers for Disease Control and Prevention (CDC). Notes from the field: transplant-transmitted Balamuthia mandrillaris—Arizona, 2010. MMWR Morb Mortal Wkly Rep 2010; 59 (36) 1182
    PubMedGoogle Scholar
  • 25 Centers for Disease Control and Prevention (CDC). Balamuthia mandrillaris transmitted through organ transplantation—Mississippi, 2009. MMWR Morb Mortal Wkly Rep 2010; 59 (36) 1165-1170
    PubMedGoogle Scholar
  • 26 Centers for Disease Control and Prevention (CDC). HIV transmitted from a living organ donor—New York City, 2009. MMWR Morb Mortal Wkly Rep 2011; 60 (10) 297-301
    PubMedGoogle Scholar
  • 27 Ison MG, Llata E, Conover CS , et al; HIV-HCV Transplantation Transmission Investigation Team. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant 2011; 11 (6) 1218-1225
    CrossrefPubMedGoogle Scholar
  • 28 Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med 2011; 364 (20) 1943-1954
    CrossrefPubMedGoogle Scholar
  • 29 Morris MI, Fischer SA, Ison MG. Infections transmitted by transplantation. Infect Dis Clin North Am 2010; 24 (2) 497-514
    CrossrefPubMedGoogle Scholar
  • 30 Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl 2003; 9 (5) 451-462
    CrossrefPubMedGoogle Scholar
  • 31 Freeman RB, Giatras I, Falagas ME , et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999; 68 (8) 1107-1111
    CrossrefPubMedGoogle Scholar
  • 32 Lumbreras C, Sanz F, González A , et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. Clin Infect Dis 2001; 33 (5) 722-726
    CrossrefPubMedGoogle Scholar
  • 33 López-Navidad A, Domingo P, Caballero F, González C, Santiago C. Successful transplantation of organs retrieved from donors with bacterial meningitis. Transplantation 1997; 64 (2) 365-368
    CrossrefPubMedGoogle Scholar
  • 34 Satoi S, Bramhall SR, Solomon M , et al. The use of liver grafts from donors with bacterial meningitis. Transplantation 2001; 72 (6) 1108-1113
    CrossrefPubMedGoogle Scholar
  • 35 Singh N. Impact of donor bacteremia on outcome in organ transplant recipients. Liver Transpl 2002; 8 (10) 975-976
    CrossrefPubMedGoogle Scholar
  • 36 Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004; 10 (7) 844-849
    CrossrefPubMedGoogle Scholar
  • 37 Linares L, García-Goez JF, Cervera C , et al. Early bacteremia after solid organ transplantation. Transplant Proc 2009; 41 (6) 2262-2264
    CrossrefPubMedGoogle Scholar
  • 38 Linares L, Cervera C, Hoyo I , et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc 2010; 42 (8) 2941-2943
    CrossrefPubMedGoogle Scholar
  • 39 Shi SH, Kong HS, Xu J , et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009; 11 (5) 405-412
    CrossrefPubMedGoogle Scholar
  • 40 Bellier C, Bert F, Durand F , et al. Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int 2008; 21 (8) 755-763
    CrossrefPubMedGoogle Scholar
  • 41 Bert F, Larroque B, Paugam-Burtz C , et al. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl 2010; 16 (3) 393-401
    PubMedGoogle Scholar
  • 42 Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009; 9 (4) 835-843
    CrossrefPubMedGoogle Scholar
  • 43 Patel G, Perez F, Bonomo RA. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: assessing their impact on organ transplantation. Curr Opin Organ Transplant 2010 Oct 7. [Epub ahead of print]
    PubMedGoogle Scholar
  • 44 Russell DL, Flood A, Zaroda TE , et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 2008; 8 (8) 1737-1743
    CrossrefPubMedGoogle Scholar
  • 45 Trottier V, Namias N, Pust DG , et al. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt) 2007; 8 (4) 437-443
    CrossrefPubMedGoogle Scholar
  • 46 Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis 2010; 12 (1) 87-93
    CrossrefPubMedGoogle Scholar
  • 47 Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29 (12) 1099-1106
    CrossrefPubMedGoogle Scholar
  • 48 Nguyen M, Eschenauer GA, Bryan M , et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010; 67 (2) 180-184
    CrossrefPubMedGoogle Scholar
  • 49 Woodford N, Dallow JW, Hill RL , et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007; 29 (4) 456-459
    CrossrefPubMedGoogle Scholar
  • 50 Lopez JA, Correa A, Navon-Venezia S , et al. Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain. Clin Microbiol Infect 2011; 17 (1) 52-56
    CrossrefPubMedGoogle Scholar
  • 51 Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 2006; 43 (3) e26-e28
    CrossrefPubMedGoogle Scholar
  • 52 Kumarasamy KK, Toleman MA, Walsh TR , et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10 (9) 597-602
    CrossrefPubMedGoogle Scholar
  • 53 Bennett JW, Herrera ML, Lewis II JS, Wickes BW, Jorgensen JH. KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother 2009; 53 (1) 292-294
    CrossrefPubMedGoogle Scholar
  • 54 Mathers AJ, Cox HL, Bonatti H , et al. Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis 2009; 11 (3) 257-265
    CrossrefPubMedGoogle Scholar
  • 55 Sidjabat HE, Silveira FP, Potoski BA , et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis 2009; 49 (11) 1736-1738
    CrossrefPubMedGoogle Scholar
  • 56 Reid GE, Grim SA, Sankary H, Benedetti E, Oberholzer J, Clark NM. Early intra-abdominal infections associated with orthotopic liver transplantation. Transplantation 2009; 87 (11) 1706-1711 DOI: 10.097/TP.0b013e3181a60338.
    CrossrefPubMedGoogle Scholar
  • 57 Lee S-O, Kang SH, Abdel-Massih RC, Brown RA, Razonable RR. Spectrum of early-onset and late-onset bacteremias after liver transplantation: implications for management. Liver Transpl 2011; 17 (6) 733-741
    CrossrefPubMedGoogle Scholar
  • 58 Pungpapong S, Alvarez S, Hellinger WC , et al. Peritonitis after liver transplantation: incidence, risk factors, microbiology profiles, and outcome. Liver Transpl 2006; 12 (8) 1244-1252
    CrossrefPubMedGoogle Scholar
  • 59 Asensio A, Ramos A, Cuervas-Mons V , et al; Red de Estudio de la Infección en el Trasplante - Grupo de Estudio de la Infección en el Trasplante. Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl 2008; 14 (6) 799-805
    CrossrefPubMedGoogle Scholar
  • 60 Said A, Safdar N, Lucey MR , et al. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant 2004; 4 (4) 574-582
    CrossrefPubMedGoogle Scholar
  • 61 Safdar N, Said A, Lucey MR , et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin Infect Dis 2004; 39 (4) 517-525
    CrossrefPubMedGoogle Scholar
  • 62 Pappas PG, Alexander BD, Andes DR , et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50 (8) 1101-1111
    CrossrefPubMedGoogle Scholar
  • 63 Pappas PG, Silveira FP ; AST Infectious Diseases Community of Practice. Candida in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4) S173-S179
    CrossrefPubMedGoogle Scholar
  • 64 Neofytos D, Fishman JA, Horn D , et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12 (3) 220-229
    CrossrefPubMedGoogle Scholar
  • 65 Collins LA, Samore MH, Roberts MS , et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170 (3) 644-652
    CrossrefPubMedGoogle Scholar
  • 66 Husain S, Tollemar J, Dominguez EA , et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75 (12) 2023-2029
    CrossrefPubMedGoogle Scholar
  • 67 Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006; 12 (5) 850-858
    CrossrefPubMedGoogle Scholar
  • 68 Lumbreras C, Cuervas-Mons V, Jara P , et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174 (3) 583-588
    CrossrefPubMedGoogle Scholar
  • 69 Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131 (10) 729-737
    PubMedGoogle Scholar
  • 70 Pappas PG, Kauffman CA, Andes D , et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 (5) 503-535
    CrossrefPubMedGoogle Scholar
  • 71 Pappas PG, Rex JH, Sobel JD , et al; Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38 (2) 161-189
    CrossrefPubMedGoogle Scholar
  • 72 Mora-Duarte J, Betts R, Rotstein C , et al; Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347 (25) 2020-2029
    CrossrefPubMedGoogle Scholar
  • 73 Reboli AC, Rotstein C, Pappas PG , et al; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356 (24) 2472-2482
    CrossrefPubMedGoogle Scholar
  • 74 Singh N, Avery RK, Munoz P , et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36 (1) 46-52
    CrossrefPubMedGoogle Scholar
  • 75 Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson Jr RH. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis 1983; 148 (2) 230-238
    CrossrefPubMedGoogle Scholar
  • 76 Montoya JG, Chaparro SV, Celis D , et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis 2003; 37 (Suppl 3) S281-S292
    CrossrefPubMedGoogle Scholar
  • 77 Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18 (1) 44-69
    CrossrefPubMedGoogle Scholar
  • 78 Singh N, Arnow PM, Bonham A , et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64 (5) 716-720
    CrossrefPubMedGoogle Scholar
  • 79 Singh N, Pruett TL, Houston S , et al. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl 2006; 12 (8) 1205-1209
    CrossrefPubMedGoogle Scholar
  • 80 Singh N, Husain S ; AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4) S180-S191
    CrossrefPubMedGoogle Scholar
  • 81 Fortún J, Martín-Dávila P, Moreno S , et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8 (11) 1065-1070
    CrossrefPubMedGoogle Scholar
  • 82 Gavalda J, Len O, San Juan R , et al; RESITRA (Spanish Network for Research on Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41 (1) 52-59
    CrossrefPubMedGoogle Scholar
  • 83 Singh N, Limaye AP, Forrest G , et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 2006; 44 (5) 445-449
    CrossrefPubMedGoogle Scholar
  • 84 Fortún J, Martín-Davila P, Moreno S , et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52 (5) 813-819
    CrossrefPubMedGoogle Scholar
  • 85 Fortún J, Martín-Dávila P, Montejo M , et al; GESITRA Study Group. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009; 87 (3) 424-435
    CrossrefPubMedGoogle Scholar
  • 86 Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78 (2) 123-138
    CrossrefPubMedGoogle Scholar
  • 87 Fortun J, Martin-Davila P, Alvarez ME , et al; Ramon y Cajal Hospital's Liver Transplant Group. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001; 71 (1) 145-149
    CrossrefPubMedGoogle Scholar
  • 88 Kwak EJ, Husain S, Obman A , et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42 (1) 435-438
    CrossrefPubMedGoogle Scholar
  • 89 Fortún J, Martín-Dávila P, Alvarez ME , et al. False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation 2009; 87 (2) 256-260 DOI: 10.1097/TP.0b013e31819288d5.
    CrossrefPubMedGoogle Scholar
  • 90 Kawagishi N, Satoh K, Enomoto Y , et al. Risk factors and impact of beta-D glucan on invasive fungal infection for the living donor liver transplant recipients. Tohoku J Exp Med 2006; 209 (3) 207-215
    CrossrefPubMedGoogle Scholar
  • 91 Herbrecht R, Denning DW, Patterson TF , et al; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6) 408-415
    CrossrefPubMedGoogle Scholar
  • 92 Walsh TJ, Anaissie EJ, Denning DW , et al; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (3) 327-360
    CrossrefPubMedGoogle Scholar
  • 93 Walsh TJ, Raad I, Patterson TF , et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44 (1) 2-12
    CrossrefPubMedGoogle Scholar
  • 94 Denning DW, Marr KA, Lau WM , et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53 (5) 337-349
    CrossrefPubMedGoogle Scholar
  • 95 Alexander BD, Perfect JR, Daly JS , et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008; 86 (6) 791-796
    CrossrefPubMedGoogle Scholar
  • 96 Singh N, Limaye AP, Forrest G , et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81 (3) 320-326 DOI: 10.1097/01.tp.0000202421.94822.f7.
    CrossrefPubMedGoogle Scholar
  • 97 Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 8 (2) 426-431
    CrossrefPubMedGoogle Scholar
  • 98 Singh N, Forrest G ; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4) S192-S198
    CrossrefPubMedGoogle Scholar
  • 99 Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7 (3) 375-381
    CrossrefPubMedGoogle Scholar
  • 100 Baddley JW, Schain DC, Gupte AA , et al. Transmission of Cryptococcus neoformans by organ transplantation. Clin Infect Dis 2011; 52 (4) e94-e98
    CrossrefPubMedGoogle Scholar
  • 101 Sun H-Y, Alexander BD, Lortholary O , et al; Cryptococcal Collaborative Transplant Study Group. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis 2010; 51 (9) 1062-1069
    CrossrefPubMedGoogle Scholar
  • 102 Sun H-Y, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis 2009; 48 (11) 1566-1576
    CrossrefPubMedGoogle Scholar
  • 103 Sun H-Y, Alexander BD, Lortholary O , et al; Cryptococcal Collaborative Transplant Study Group. Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol 2010; 48 (6) 785-791
    CrossrefPubMedGoogle Scholar
  • 104 Singh N, Alexander BD, Lortholary O , et al; Cryptococcal Collaborative Transplant Study Group. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195 (5) 756-764
    CrossrefPubMedGoogle Scholar
  • 105 Singh N, Alexander BD, Lortholary O , et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008; 46 (2) e12-e18
    PubMedGoogle Scholar
  • 106 Pappas PG, Perfect JR, Cloud GA , et al. Cryptococcus in HIV-negative patients in era of effective azole therapy. Clin Infect Dis 2001; 33: 690-699
    CrossrefPubMedGoogle Scholar
  • 107 Perfect JR, Dismukes WE, Dromer F , et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50 (3) 291-322
    CrossrefPubMedGoogle Scholar
  • 108 Sun H-Y, Alexander BD, Lortholary O , et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009; 49 (11) 1721-1728
    CrossrefPubMedGoogle Scholar
  • 109 Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008; 47 (10) 1321-1327
    CrossrefPubMedGoogle Scholar
  • 110 Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis 2003; 5 (3) 140-143
    CrossrefPubMedGoogle Scholar
  • 111 Singh N, Lortholary O, Alexander BD , et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005; 80 (8) 1033-1039
    CrossrefPubMedGoogle Scholar
  • 112 Sun H-Y, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis 2011; 53 (2) 168-176
    CrossrefPubMedGoogle Scholar
  • 113 Singh N, Lortholary O, Alexander BD , et al; Cryptococcal Collaborative Transplant Study Group. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40 (12) 1756-1761
    CrossrefPubMedGoogle Scholar
  • 114 Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17 (4) 770-782
    CrossrefPubMedGoogle Scholar
  • 115 Radisic M, Lattes R, Chapman JF , et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5 (2) 84-93
    CrossrefPubMedGoogle Scholar
  • 116 Martin SI, Fishman JA ; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4) S227-S233
    CrossrefPubMedGoogle Scholar
  • 117 Kovacs JA, Hiemenz JW, Macher AM , et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100 (5) 663-671
    CrossrefPubMedGoogle Scholar
  • 118 Sing A, Trebesius K, Roggenkamp A , et al. Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups. J Clin Microbiol 2000; 38 (4) 1461-1467
    PubMedGoogle Scholar
  • 119 Hauser PM, Bille J, Lass-Flörl C , et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol 2011; 49 (5) 1872-1878
    CrossrefPubMedGoogle Scholar
  • 120 Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113 (5) 1215-1224
    CrossrefPubMedGoogle Scholar
  • 121 Delclaux C, Zahar JR, Amraoui G , et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis 1999; 29 (3) 670-672
    CrossrefPubMedGoogle Scholar
  • 122 Mofenson LM, Brady MT, Danner SP , et al; Centers for Disease Control and Prevention; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58 (RR-11) 1-166
    PubMedGoogle Scholar
  • 123 Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17 (4) 770-782
    CrossrefPubMedGoogle Scholar
  • 124 Husni RN, Gordon SM, Longworth DL , et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26 (3) 753-755
    CrossrefPubMedGoogle Scholar
  • 125 Freeman Jr RB. The ’indirect’ effects of cytomegalovirus infection. Am J Transplant 2009; 9 (11) 2453-2458
    CrossrefPubMedGoogle Scholar
  • 126 Kotton CN, Kumar D, Caliendo AM , et al; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89 (7) 779-795 DOI: 10.1097/TP.0b013e3181cee42f.
    CrossrefPubMedGoogle Scholar
  • 127 Humar A, Snydman D ; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4) S78-S86
    CrossrefPubMedGoogle Scholar
  • 128 Paya C, Humar A, Dominguez E , et al; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4 (4) 611-620
    CrossrefPubMedGoogle Scholar
  • 129 Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43 (7) 869-880
    CrossrefPubMedGoogle Scholar
  • 130 Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143 (12) 870-880
    CrossrefPubMedGoogle Scholar
  • 131 Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8 (10) 2111-2118
    CrossrefPubMedGoogle Scholar
  • 132 Hodson EM, Jones CA, Webster AC , et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365 (9477) 2105-2115
    CrossrefPubMedGoogle Scholar
  • 133 Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl 2009; 15 (8) 963-967
    CrossrefPubMedGoogle Scholar
  • 134 Arthurs SK, Eid AJ, Pedersen RA , et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46 (6) 840-846
    CrossrefPubMedGoogle Scholar
  • 135 Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79 (1) 85-90
    CrossrefPubMedGoogle Scholar
  • 136 Limaye AP, Bakthavatsalam R, Kim HW , et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78 (9) 1390-1396
    CrossrefPubMedGoogle Scholar
  • 137 Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 2008; 10 (1) 13-18
    CrossrefPubMedGoogle Scholar
  • 138 Babel N, Gabdrakhmanova L, Juergensen JS , et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation 2004; 78 (2) 283-285
    PubMedGoogle Scholar
  • 139 Fellay J, Venetz JP, Aubert JD, Seydoux C, Pascual M, Meylan PRA. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Transplant Proc 2005; 37 (2) 949-951
    CrossrefPubMedGoogle Scholar
  • 140 Åsberg A, Humar A, Rollag H , et al; VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7 (9) 2106-2113
    CrossrefPubMedGoogle Scholar
  • 141 Len O, Gavaldà J, Aguado JM , et al; RESITRA. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis 2008; 46 (1) 20-27
    CrossrefPubMedGoogle Scholar
  • 142 Åsberg A, Humar A, Jardine AG , et al; VICTOR Study Group. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9 (5) 1205-1213
    CrossrefPubMedGoogle Scholar
  • 143 Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010; 10 (1) 157-161
    CrossrefPubMedGoogle Scholar
  • 144 Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35 (7) 866-872
    CrossrefPubMedGoogle Scholar
  • 145 Peleg AY, Husain S, Qureshi ZA , et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44 (10) 1307-1314
    CrossrefPubMedGoogle Scholar
  • 146 Nocardia infections. Am J Transplant 2004; 4 (Suppl 10) 47-50
    CrossrefPubMedGoogle Scholar
  • 147 Jodlowski TZ, Melnychuk I, Conry J. Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother 2007; 41 (10) 1694-1699
    CrossrefPubMedGoogle Scholar
  • 148 Moylett EH, Pacheco SE, Brown-Elliott BA , et al. Clinical experience with linezolid for the treatment of nocardia infection. Clin Infect Dis 2003; 36 (3) 313-318
    CrossrefPubMedGoogle Scholar
  • 149 Larruskain J, Idigoras P, Marimón JM, Pérez-Trallero E. Susceptibility of 186 Nocardia sp. isolates to 20 antimicrobial agents. Antimicrob Agents Chemother 2011; 55 (6) 2995-2998
    CrossrefPubMedGoogle Scholar
  • 150 Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27 (5) 1266-1277
    CrossrefPubMedGoogle Scholar
  • 151 Torre-Cisneros J, Doblas A, Aguado JM , et al; Spanish Network for Research in Infectious Diseases. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48 (12) 1657-1665
    CrossrefPubMedGoogle Scholar
  • 152 Aguado JM, Torre-Cisneros J, Fortún J , et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48 (9) 1276-1284
    CrossrefPubMedGoogle Scholar
  • 153 Mycobacterium tuberculosis. Am J Transplant 2004; 4 (Suppl 10) 37-41
    CrossrefPubMedGoogle Scholar
  • 154 Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40 (4) 581-587
    CrossrefPubMedGoogle Scholar
  • 155 Centers for Disease Control and Prevention (CDC). Transplantation-transmitted tuberculosis—Oklahoma and Texas, 2007. MMWR Morb Mortal Wkly Rep 2008; 57 (13) 333-336
    PubMedGoogle Scholar
  • 156 John GT, Shankar V, Abraham AM, Mukundan U, Thomas PP, Jacob CK. Risk factors for post-transplant tuberculosis. Kidney Int 2001; 60 (3) 1148-1153
    CrossrefPubMedGoogle Scholar
  • 157 Benito N, Sued O, Moreno A , et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002; 74 (10) 1381-1386
    CrossrefPubMedGoogle Scholar
  • 158 Manuel O, Humar A, Preiksaitis J , et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007; 7 (12) 2797-2801
    CrossrefPubMedGoogle Scholar
  • 159 Yehia BR, Blumberg EA. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl 2010; 16 (10) 1129-1135
    CrossrefPubMedGoogle Scholar
  • 160 Jafri S-M, Singal AG, Kaul D, Fontana RJ. Detection and management of latent tuberculosis in liver transplant patients. Liver Transpl 2011; 17 (3) 306-314
    CrossrefPubMedGoogle Scholar
  • 161 Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007; 83 (12) 1557-1562
    CrossrefPubMedGoogle Scholar
  • 162 Subramanian A, Dorman S ; AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4) S57-S62
    CrossrefPubMedGoogle Scholar
  • 163 Horsburgh Jr CR, Rubin EJ. Clinical practice: latent tuberculosis infection in the United States. N Engl J Med 2011; 364 (15) 1441-1448
    CrossrefPubMedGoogle Scholar
  • 164 American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52 (RR-11) 1-77
    PubMedGoogle Scholar
  • 165 Holty J-EC, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009; 15 (8) 894-906
    CrossrefPubMedGoogle Scholar
  • 166 Schluger LK, Sheiner PA, Jonas M , et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996; 63 (5-6) 364-369
    PubMedGoogle Scholar
  • 167 Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation 2000; 69 (1) 64-69
    CrossrefPubMedGoogle Scholar
  • 168 Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39 (5) 743-746
    CrossrefPubMedGoogle Scholar
  • 169 Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350 (9) 950-952
    CrossrefPubMedGoogle Scholar
  • 170 Stelzmueller I, Lass-Floerl C, Geltner C , et al. Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients. Transpl Int 2008; 21 (6) 534-546
    CrossrefPubMedGoogle Scholar
  • 171 Husain S, Alexander BD, Munoz P , et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37 (2) 221-229
    CrossrefPubMedGoogle Scholar
  • 172 Sun HY, Aguado JM, Bonatti H , et al; Zygomycosis Transplant Study Group. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant 2009; 9 (9) 2166-2171
    CrossrefPubMedGoogle Scholar
  • 173 Singh N, Aguado JM, Bonatti H , et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200 (6) 1002-1011
    CrossrefPubMedGoogle Scholar
  • 174 Hammer GS, Bottone EJ, Hirschman SZ. Mucormycosis in a transplant recipient. Am J Clin Pathol 1975; 64 (3) 389-398
    PubMedGoogle Scholar
  • 175 Sun H-Y, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis 2011; 11 (4) 301-311
    CrossrefPubMedGoogle Scholar
  • 176 Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards Jr J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48 (12) 1743-1751
    CrossrefPubMedGoogle Scholar
  • 177 Reed C, Bryant R, Ibrahim AS , et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47 (3) 364-371
    CrossrefPubMedGoogle Scholar